Non-interventional Study Describing Patients' Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Atrial fibrillation; Stroke
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 28 Nov 2017 Planned End Date changed from 10 Dec 2017 to 29 Dec 2017.
- 28 Nov 2017 Planned primary completion date changed from 10 Dec 2017 to 29 Dec 2017.
- 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.